These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1874 related articles for article (PubMed ID: 28303724)

  • 1. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.
    Cobbina E; Akhlaghi F
    Drug Metab Rev; 2017 May; 49(2):197-211. PubMed ID: 28303724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steatosis and NASH in type 2 diabetes.
    Hu M; Phan F; Bourron O; Ferré P; Foufelle F
    Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
    Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
    Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK
    Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
    Buzzetti E; Pinzani M; Tsochatzis EA
    Metabolism; 2016 Aug; 65(8):1038-48. PubMed ID: 26823198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats.
    Shen Y; Liu J; Yao B; Zhang Y; Huang S; Liang C; Huang J; Tang Y; Wang X
    Toxicol Lett; 2024 May; 396():36-47. PubMed ID: 38663832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease.
    Song BJ; Akbar M; Jo I; Hardwick JP; Abdelmegeed MA
    Adv Pharmacol; 2015; 74():303-72. PubMed ID: 26233911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis].
    Berlanga A; Guiu-Jurado E; Porras JA; Aragonès G; Auguet T
    Clin Investig Arterioscler; 2016; 28(1):47-61. PubMed ID: 26049666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of CYP2E1 in non-alcoholic fatty liver diseases.
    Aljomah G; Baker SS; Liu W; Kozielski R; Oluwole J; Lupu B; Baker RD; Zhu L
    Exp Mol Pathol; 2015 Dec; 99(3):677-81. PubMed ID: 26551085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications.
    Okubo H; Kushiyama A; Nakatsu Y; Yamamotoya T; Matsunaga Y; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Asano T
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Mansell SE; Kim RB; Tirona RG; Beaton MD
    Drug Metab Dispos; 2015 Oct; 43(10):1484-90. PubMed ID: 26231377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis.
    Spahis S; Delvin E; Borys JM; Levy E
    Antioxid Redox Signal; 2017 Apr; 26(10):519-541. PubMed ID: 27452109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.